BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

Stock Information for Brainstorm Cell Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Brainstorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.